By Elaine Chen, Allison DeAngelis, and Adam Feuerstein

Sept. 5, 2024

How effective is Summit Therapeutics’ lung cancer immunotherapy? Why are obesity drugmakers turning back to a two-decade-old idea? And how long will Elaine last as a new (official) co-host?

We talk about all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We discuss the next big trend in obesity drug development — treatments that target the amylin hormone. Companies argue that these types of drugs could lead to less nausea and muscle loss, and the first big readout is coming later this year.

advertisement

We also chat about an upcoming presentation from Summit Therapeutics on its cancer drug that beat Merck’s Keytruda, mixed data from Recursion’s lead AI-derived drug candidate, and more news in the life sciences.

For more on amylin obesity drugs, go here; for a detailed preview on Summit’s presentation, go here; for more on Recursion’s mixed results, go here; and to learn more about the full data from Alnylam’s HELIOS-B trial , go here.

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

advertisement

, ,
Submit a correction requestReprints

  1. Elaine Chen

    National Biotech Reporter

    Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

  2. Allison DeAngelis

    Biotech Startups and Venture Capital Reporter

    Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

  3. Adam Feuerstein

    Senior Writer, Biotech

    Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.